The DOI matches its Crossref record; the references it cites are not checked yet.
Crystallographic Analysis Reveals that Anticancer Clinical Candidate L-778,123 Inhibits Protein Farnesyltransferase and Geranylgeranyltransferase-I by Different Binding Modes
Abstract
Many signal transduction proteins that control growth, differentiation, and transformation, including Ras GTPase family members, require the covalent attachment of a lipid group by protein farnesyltransferase (FTase) or protein geranylgeranyltransferase type-I (GGTase-I) for proper function and for the transforming activity of oncogenic mutants. FTase inhibitors are a new class of potential cancer therapeutics under evaluation in human clinical trials. Here, we present crystal structures of the clinical candidate L-778,123 complexed with mammalian FTase and complexed with the related GGTase-I enzyme. Although FTase and GGTase-I have very similar active sites, L-778,123 adopts different binding modes in the two enzymes; in FTase, L-778,123 is competitive with the protein substrate, whereas in GGTase-I, L-778,123 is competitive with the lipid substrate and inhibitor binding is synergized by tetrahedral anions. A comparison of these complexes reveals that small differences in protein structure can dramatically affect inhibitor binding and selectivity. These structures should facilitate the design of more specific inhibitors toward FTase or GGTase-I. Finally, the binding of a drug and anion together could be applicable for developing new classes of inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, some high potency inhibitors coordinate Zn2+ via uncharged nitrogens with electron lone pairs, such as those found in sulfonamides18 and imidazoles6 (see Figure 13), that seem to interact more strongly than negatively charged nitro groups.7”
From AutoDock4Zn: An Improved AutoDock Force Field for Small-Molecule Docking to Zinc Metalloproteins (2014) · cites this paper as [6]
Citations
Cites
None of the references could be matched to a known paper.
Research works printed but not linked: 53
- Tamanoi F., 2001, The Enzymes, 322
- Haluska P., Eur. J. Cancer, 38, 1700
- Caponigro F., 2003, Expert Opin. Invest. Drugs 12, 943−954.
- Cortes J. E., 2002, ZARNESTRATM (R115777), in chronic myeloid leukemia and other other hematological malignancies, Blood 31, 31.
- Fu H. W., 1999, Recent Prog. Horm. Res. 54, 315−342.
- Barbacid M., 1987, Annu. Rev. Biochem. 56, 779−827.
- Kato K., 1992, Proc. Natl. Acad. Sci. U.S.A. 89
- Cox A. D., 2001, Drugs 61, 723−732.
- Long S. B., 1998, Biochemistry 37, 9612−9618.
- Long S. B., 2000, Structure 8, 209−222.
- Strickland C. L., 1998, Biochemistry 37, 16601−16611.
- Park H.-W., 1800, Science, 275, 1804
- Long S. B., 2002, Nature 419, 645−650.
- Taylor J. S., EMBO J., 22, 5974
- Long S. B., 2001, Proc. Natl. Acad. Sci. U.S.A. 98
- Bell I. M., J. Med. Chem., 45, 2409
- deSolms S. J., J. Med. Chem., 46, 2984
- Strickland C. L., J. Med. Chem., 42, 2135
- Reiss Y., 1990, Inhibition of purified
- Dinsmore C. J., 2003, Chem. 3, 1075−1093.
- Sebti S. M., 2000, Oncogene 19, 6584−6593.
- Dinsmore C. J., J. Am. Chem. Soc., 123, 2108
- Huber H. E., J. Biol. Chem., 276, 24465
- Zhang F. L., J. Biol. Chem., 269, 23470
- Otwinowski Z., 1997, Methods Enzymol. 276A, 307−326.
- Brünger A. T., 1998, Acta Crystallogr., Sect. D 54, 905−921.
- Jones T. A., 1993, The manual
- Word J. M., J. Mol. Biol., 285, 1733
- Guex N., 1997, Electrophoresis 18, 2714−2723.
- De Moliner E., Eur. J. Biochem., 270, 3181
- Vogt A., 1991, Oncogene, 13, 1999
- Stark W. W., Jr., Am. J. Physiol., 275, L63
- Sun J., 2003, Cancer Res. 63, 8922−8929.
- Walters C. E., J. Immunol., 168, 4094
- Lobell R. B., 2001, Cancer Res. 61, 8758−8768.
- Wong W. W., 2002, Leukemia 16, 508−519.
- Reid T. S., 2004, Biochemistry 43, 6877−6884.
- Del Villar K., J. Biol. Chem., 274, 27017
- Buckner F. S., 2002, Mol. Biochem. Parasitol. 122, 181−188.
- Murthi K. K., 1935, Bioorg. Med. Chem. Lett., 13, 1937
- Chakrabarti D., 1998, Mol. Biochem. Parasitol. 94, 175−184.
- Segel, I. H. (1975)Enzyme Kinetics: Behaviour and Analysis of Rapid Equilibrium and Steady-State Systems, pp 465−504, Wiley, New York.
- Theorell H., 1965, Arch. Biochem. Biophys. 110, 413−421.
- Pylypenko O., 2003, Mol. Cell 11, 483−494.
- Zhang H., 2000, Structure 8, 241−251.
- Scholten J. D., J. Biol. Chem., 272, 18081
- Hajduk P. J., J. Med. Chem., 43, 4786
- Szczepankiewicz B. G., J. Am. Chem. Soc., 125, 4096
- Erlanson D. A., 2000, Proc. Natl. Acad. Sci. U.S.A. 97
- Seidel H. M., 1994, Biochemistry 33, 5641−5646.
- Zhou G., 1998, Proc. Natl. Acad. Sci. U.S.A. 95
- Milner-White E. J., Biochem. J., 122, 740
- Abbreviations FPP, farnesyl diphosphate
Cited by
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
Fleming, F. F., Yao, L., Ravikumar, P. C., Funk, L., & Shook, B. C. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100762r · Cited by 1,754
Konstantinopoulos, P. A., Karamouzis, M. V., & Papavassiliou, A. G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2221 · Cited by 451
“The CAAX mimetic FTI L778123 has been shown to bear significant inhibitory activity against GGTase I (besides FTase”
BackgroundInhibition of Ras for Cancer Treatment: The Search Continues
Baines, A. T., Xu, D., & Der, C. J. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.121 · Cited by 382
AutoDock4Zn: An Improved AutoDock Force Field for Small-Molecule Docking to Zinc Metalloproteins
Santos-Martins, D., Forli, S., Ramos, M. J., & Olson, A. J. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500209e · Cited by 318
Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors
Basso, A. D., Kirschmeier, P., & Bishop, W. R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500012-jlr200 · Cited by 297
Metadata
- Authors
- Reid, T. S., Long, S. B., & Beese, L. S.
- Affiliations
- Duke Medical Center (US)
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2004-06-23
- Volume
- 43
- Issue
- 28
- Pages
- 9000-9008
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2016552910
- Cited by
- 51
- References
- 1
- Citations by year
- 2026: 2 · 2023: 2 · 2022: 3 · 2020: 5 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 3 · 2013: 3 · 2012: 2
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM52382)
- National Center for Research Resources (RR07 707)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- farnesyltransferase, geranylgeranyltransferase I, Ras GTPase, lipid modification, competitive inhibition, tetrahedral anions, enzyme selectivity, crystal structure, anticancer drug design
- MeSH terms
- Animals, Antineoplastic Agents, Binding, Competitive, Enzyme Inhibitors, Humans, Imidazoles, Models, Molecular, Protein Binding, Protein Conformation, Structure-Activity Relationship, Crystallography, X-Ray, Alkyl and Aryl Transferases, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Crystallographic Analysis Reveals that Anticancer Clinical Candidate L-778,123 Inhibits Protein Farnesyltransferase and Geranylgeranyltransferase-I by Different Binding Modes. https://app.cochat.ai/papers/10.1021/bi049280b
- The paper
- Reid, T. S., Long, S. B., & Beese, L. S. (2004). Crystallographic Analysis Reveals that Anticancer Clinical Candidate L-778,123 Inhibits Protein Farnesyltransferase and Geranylgeranyltransferase-I by Different Binding Modes. Biochemistry. https://doi.org/10.1021/bi049280b
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.